Trial Profile
A randomised, open-label, parallel, phase II trial evaluating the efficacy of aprepitant in patients with gynaecological cancer after postoperative adjuvant chemotherapy with paclitaxel and carboplatin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2015
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Dexamethasone; Serotonin 3 receptor antagonists
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 05 Nov 2015 New trial record